Article

Daily OTC Pearl: Sacubitril and Valsartan (Entresto)

Sacubitril and Valsartan (Entresto) is indicated to reduce the risk of cardiovascular death and hospitalization in adult patients with chronic heart failure.

Medication Pearl of the Day: Sacubitril and Valsartan (Entresto)

Indication: Sacubitril and Valsartan (Entresto) is indicated to reduce the risk of cardiovascular death and hospitalization in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction below normal.

Insight:

  • Dosing: Initiate low dose and increase to higher dose every 2 weeks.
  • Dosage forms: Film-coated tablets 24/26 mg; 49/51 mg; 97/103 mg.
  • Adverse events: Adverse reactions occurring ≥ 5% are hypotension, hyperkalemia, cough, dizziness, and renal failure.
  • Mechanism of action: Entresto contains a neprilysin inhibitor, sacubitril, and an angiotensin receptor blocker, valsartan. Entresto inhibits neprilysin (neutral endopeptidase; NEP) via LBQ657, the active metabolite of the prodrug sacubitril, and blocks the angiotensin II type-1 receptor via valsartan.

Source: entresto.pdf (novartis.us)

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Image credit:  Artur | stock.adobe.com
Cardiovascular disease doctor or cardiologist holding red heart in clinic or hospital exam room office for csr professional medical service, cardiology health care and world heart health day concept - Image credit: Chinnapong | stock.adobe.com
Image credit:  kitsawet | stock.adobe.com
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com